Want to see SE:XINT full AI Analyst Report?
XINT Stock Chart & Stats
kr0.28
-kr0.02(-4.02%)
At close: 4:00 PM EST
kr0.28
-kr0.02(-4.02%)
Day’s Range― - ―
52-Week Rangekr0.15 - kr0.53
Previous CloseN/A
Volume22.80K
Average Volume (3M)293.62K
Market Cap
kr137.80M
Enterprise Valuekr172.39
Total Cash (Recent Filing)kr30.72M
Total Debt (Recent Filing)kr30.00M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding861,266,850
10 Day Avg. Volume214,068
30 Day Avg. Volume293,619
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)kr11.13M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt reduces refinancing pressure and interest obligations, giving the company more flexibility than a similarly loss-making biotech with leverage. This does not eliminate funding needs, but it limits creditor claims on future assets and preserves strategic financing options.
ITGA10 Platform Across Two FieldsA platform centered on the ITGA10 receptor supports development across regenerative medicine and oncology rather than relying on only one therapeutic application. This breadth can create multiple partnering or commercialization pathways if the underlying target continues to validate clinically.
Positive Recent Gross ProfitPositive gross profit in the two most recent reported years indicates that some revenue has exceeded directly associated costs, an encouraging foundation for eventual operating leverage. However, this benefit remains limited while revenue is small and overall operating expenses continue to produce substantial losses.
Bears Say
Persistent Operating LossesDeep and persistent EBIT and net losses show that the current business has not yet converted its research platform into sustainable profitability. Continued losses can require repeated financing, dilute existing holders, and constrain investment in clinical development or commercialization over the next several quarters.
Heavy Ongoing Cash BurnConsistently heavy negative operating cash flow means the company does not currently fund its operations internally. Without a sustained improvement toward breakeven, ongoing development depends on external capital, making financing availability and terms important to maintaining the pipeline.
Negative Equity And Volatile RevenueNegative shareholders’ equity materially weakens balance-sheet resilience even without debt, while the revenue decline underscores limited and volatile commercialization traction. Together, these conditions reduce financial flexibility and increase the likelihood that future growth requires external funding.
Xintela AB News
XINT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was kr0.15 and its highest was kr0.53 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is kr137.80M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Nov 27, 2026 which is in 72 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Aug 28, 2026. The company reported -kr0.01 earnings per share for the quarter.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is 0.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -kr0.01 in its last earnings report. Following the earnings report the stock price went down -5.056%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in SE:XINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
NextCell Pharma AB
―